The current stock price of LNSR is 11.63 USD. In the past month the price increased by 13.24%. In the past year, price increased by 34.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.11 | 217.86B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.78 | 200.77B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.32 | 141.35B | ||
| SYK | STRYKER CORP | 26.69 | 134.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.46 | 55.39B | ||
| IDXX | IDEXX LABORATORIES INC | 53.65 | 54.02B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.17 | 49.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.87 | 37.36B | ||
| RMD | RESMED INC | 24.33 | 35.16B | ||
| DXCM | DEXCOM INC | 35.68 | 25.89B | ||
| PODD | INSULET CORP | 62.2 | 20.00B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.82B |
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
LENSAR INC
2800 Discovery Drive, Suite 100
Orlando FLORIDA 32826 US
CEO: Nicholas Curtis
Employees: 140
Phone: 18885367271
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 140 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The firm has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
The current stock price of LNSR is 11.63 USD.
LNSR does not pay a dividend.
LNSR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 31.56% is expected in the next year compared to the current price of 11.63.
LENSAR INC (LNSR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.39).
ChartMill assigns a technical rating of 6 / 10 to LNSR. When comparing the yearly performance of all stocks, LNSR is one of the better performing stocks in the market, outperforming 81.55% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to LNSR. LNSR may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months LNSR reported a non-GAAP Earnings per Share(EPS) of -4.39. The EPS decreased by -200.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.39% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
7 analysts have analysed LNSR and the average price target is 15.3 USD. This implies a price increase of 31.56% is expected in the next year compared to the current price of 11.63.
For the next year, analysts expect an EPS growth of -5.37% and a revenue growth 21.28% for LNSR